Q1 2024
- On 29 January 2024, Kinarus Therapeutics Holding AG and Curatis AG, a Basel-Landschaft incorporated medicine distribution and drug development company predominantly focused on orphan/ultra-orphan diseases and specialty care diseases (“Curatis”), announced that they have entered into a transaction agreement (the "Transaction Agreement") regarding a contemplated Combination Transaction.
- Under the terms of the Transaction Agreement shareholders of Curatis shall exchange each outstanding Curatis share (the “Curatis Share”) into one newly issued Kinarus Holding share.
- In the context of the Combination Transaction, it is also envisaged to implement a reverse share split in the ratio 4,480:1 as well as a capital reduction.
- Closing of the Combination Transaction is expected around the end of April 2024.
2023
- In September 2023, Kinarus Therapeutics Holding AG and its 100% subsidiary, Kinarus AG had filed for bankruptcy after a financing agreement with a Chinese investment company in May 2023 has not led to the agreed payments.
2022
- First safety review of the KINETIC trial by the Independent Data and Safety Monitoring Board (DSMB) results in recommendation to continue as planned
- Kinarus receives a grant of 7.000.000 CHF from the Programme for COVID Medicines of the Swiss Federal Office of Public Health
- Kinarus completes a reverse takeover transaction with Perfect Holding SA, with shareholders representing 95.3 % of Kinarus shares receiving newly issued shares in Perfect Holding SA (first day of listing of new shares on 3 June 2022) in exchange for a contribution in kind of their Kinarus shares
- Kinarus is issued US Patent No. 11,285,155 covering the pharmaceutical composition of KIN001 and its use in certain types of cancers, conferring protection until at least 2037
2021
- Kinarus receives approval from the German regulatory authority to start a large phase 2 clinical trial (approx. 400 patients) for the treatment of hospitalized COVID-19 patients
- Third financing from private investors as well as CHF 3.0 million convertible loan secured and used to fund the phase 2 trial of KIN001 in COVID-19 as well as the related clinical development plans
- Kinarus prepares Scientific Advice (EMA) and pre-IND meeting (FDA) for agreement on clinical and technical development and launch strategy in Europe and the US
- First patients dosed in phase 2 clinical trial of KIN001 for oral treatment of hospitalized COVID-19 patients
2020
- Kinarus generates data demonstrating potent antiviral activity of KIN001 against SARS-CoV-2
- Kinarus capitalizes on KIN001 as a potentially effective COVID-19 therapy, with the advantage of targeting multiple facets of the disease, given the drug's antiviral, anti-inflammatory, and antifibrotic activities
2019
- Composition of matter patent granted in Europe (US decision pending) for KIN001
- Second financing with private investors with proceeds used to fund the clinical development of KIN001 as well as general corporate purposes
2018
- Kinarus receives regulatory and ethics committee approval to launch a phase 2 clinical trial of KIN001 in wet AMD as an oral therapy complementing anti-VEGF agents with the objective to extend the duration between required injections
- Kinarus completes a clinical protocol for a complementary phase 2 trial in idiopathic pulmonary fibrosis (IPF), ready for regulatory submission
2017
- Pamapimod license, KIN001 as well as corresponding data carved out from Strekin
- Kinarus AG founded based on those assets
- First financing round with private investors with proceeds used to support clinical development
- Kinarus files patents for KIN001 in multiple indications
2016
- Strekin concludes licensing agreement with Roche, ensuring exclusive global rights for development of pamapimod, a phase 2 clinical P38 MAPK inhibitor
- Development of KIN001, a unique small molecule therapeutic
- Initial preclinical models for KIN001 trigger selection of disease indications for clinical development